Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.59 |
| ▸ | PPARD | Q03181 | 7/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897905 | 1.00 | PPARA (0.59) | PPARAPPARDPPARGCHRM4SMN1; SMN2 | |
| SCHEMBL3891146 | 0.88 | PPARA (0.59) | PPARAPPARDPPARGCHRM4SMN1; SMN2 | |
| SCHEMBL3888239 | 0.88 | PPARA (0.59) | PPARAPPARDPPARGCHRM4SMN1; SMN2 | |
| SCHEMBL3888243 | 0.88 | PPARA (0.59) | PPARAPPARDPPARGCHRM4SMN1; SMN2 | |
| SCHEMBL3890396 | 0.87 | PPARA (0.68) | PPARAPPARDPPARG | |
| SCHEMBL3890401 | 0.87 | PPARA (0.68) | PPARAPPARDPPARG | |
| SCHEMBL2069456 | 0.86 | PPARA (0.68) | PPARAPPARDPPARGCHRM4SMN1; SMN2 | |
| SCHEMBL3903526 | 0.82 | PPARA (0.46) | PPARA | |
| SCHEMBL3903528 | 0.82 | PPARA (0.46) | PPARA | |
| SCHEMBL27678409 | 0.81 | PPARA (0.73) | PPARAPPARDPPARGCHRM4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1862464-A1 | NOVEL CYCLIC AMINOPHENYLALKANOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036489-A1 | Novel Cyclic Aminophenylalkanoic Acid Derivative | PPARA, PPARD, PPARG | PPARA 1/4885PPARD 2/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.